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1015-9584/Copyright ª 2014, Asian SuSummary Introduction: Compared with intravenous chemotherapy, cytoreductive surgery
(CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve
survival in patients with recurrent colorectal disease confined to the peritoneum. We report
our experience with CRS and HIPEC for colorectal cancer patients with peritoneal carcinoma-
tosis, evaluating prognostic factors for disease-free survival (DFS), overall survival (OS), and
perioperative morbidity and mortality.
Methods: All patients who underwent CRS and HIPEC were included in our study. Clinical char-
acteristics, operative data, and 30-day morbidity and mortality were collected and evaluated.
Results: Between January 2001 and December 2012, there were 35 consecutive patients who
underwent CRS and HIPEC at our institution. Thirty-three patients (94%) had optimal cytore-
duction. No 30-day mortality was reported, but 14 patients had postoperative complications.
The median DFS was 9.4 months (95% confidence interval 5.5e18.7 months), and DFS at 1 year,
3 years, and 5 years were 43.8%, 22.3%, and 22.3%, respectively. The median OS was calculated
to be 27.1 months (95% confidence interval 15.3e39.1), and the OS at 1 year, 3 years, and 5
years were 83.7%, 38.2%, and 19.1%, respectively.ave no disclosures.
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66 M.C.C. Teo et al.Conclusion: CRS and HIPEC can provide survival benefit, with reasonable morbidity and mortal-
ity for Asian patients with peritoneal carcinomatosis from colorectal cancer. Patient selection
and perioperative management of the patients are key to the success of the procedure.
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reserved.1. Introduction
Colorectal peritoneal metastases (CPM) occur in up to 20% of
colorectal cancers, and 40e70% of all recurrent diseases. In
10e30% of these recurrences, the disease is confined to the
peritoneum, conferring a median survival of 7 months.1 In
these patients, cytoreductive surgery (CRS) and hyperther-
mic intraperitoneal chemotherapy (HIPEC) have been shown
to improve survival when compared to intravenous chemo-
therapy alone.2 The success of CRS and HIPEC is based on the
underlying principle of peritoneal disease being a locore-
gional disease, and not a “true”metastasis.3 Hence, surgical
resection of the entiremacroscopic tumor by CRS, and HIPEC
targeting the microscopic disease, renders the patient
potentially tumor-free. Prognostic factors include ability to
achieve complete cytoreduction,4,5 tumor burden,6 and
primary tumor histology7; therefore, patient selection is of
utmost importance. We report our (tertiary) institution’s
experiencewithCRSandHIPEC for colorectal cancer patients
with peritoneal carcinomatosis (PC), evaluating the prog-
nostic factors for disease-free survival (DFS) and overall
survival (OS) and the perioperative morbidity and mortality.
2. Methods
The study was conducted with the approval of the
Centralized Institutional Review Board of the Singapore
Health Services. Data were prospectively collected for
consecutive cases of colorectal cancer patients with PC
treated by CRS and HIPEC at the National Cancer Centre
Singapore between January 2001 and December 2012. Our
primary end points were OS and DFS. Clinical characteris-
tics, operative data, and 30-day morbidity and mortality
were also evaluated.8 All of the cases had surgery per-
formed by either one of two surgeons (K.C. S. and M. T.).
2.1. Patient selection
All patients who were selected to undergo CRS and HIPEC in
our institution were of Eastern Cooperative Group (ECOG)
performance status 0 or 1, with no distant metastases
evaluated with computed tomography (CT) or positron
emission tomography-CT scans. In addition, the primary
tumor histology and stage, the disease-free interval (DFI),
response to chemotherapy, tumor burden, and the possi-
bility of complete cytroreduction are discussed at multi-
disciplinary tumor board meetings, with radiologists,
pathologists, as well as radiation, medical, and surgical
oncologists present. The patients were also evaluated with
colonoscopy to exclude synchronous and metachronouscolonic lesions. Prior to the surgery, all patients were
subjected to a physical examination and routine blood
tests, including tumor markers.
2.2. Surgical procedure
CRS was performed as described by Sugarbaker.9 The pro-
cedure aims to remove all macroscopic peritoneal disease,
and resection of involved visceral organs is typically per-
formed first followed by the removal of sections of involved
peritoneum. Bowel anastomoses are typically performed
after HIPEC. Mitomycin C was the drug of choice for our
patients with colorectal PC.
HIPEC targets the microscopic diseases, working on le-
sions less than 3 mm. Owing to the peritonealeplasma
barrier, a higher dose of chemotherapy can be delivered
with less systemic toxicity. The high temperature increases
the drug penetration and provides a synergistic effect with
the intraperitoneal chemotherapy. At our institution, a
closed technique for HIPEC, with the chemotherapy agent
(Mitomycin C) diluted in 2e3 L of peritoneal dialysis solu-
tion at 42C, is used to distend the abdomen and ensure the
greatest exposure to the chemotherapy agent. The tem-
perature is measured via temperature probes attached to
the inflow and outflow catheters. Currently, we are using
the Belmont hyperthermia pump (Belmont Instrument
Corporation, Billerica, MA, USA) to deliver HIPEC via a sin-
gle inflow catheter, and drainage is via four intra-
abdominal drains. In our initial experience, typically only
two intra-abdominal drains were placed for drainage.
HIPEC is administered for 60 minutes. A dedicated anes-
thetist monitors the patient’s parameters, including the
core temperature via an esophageal temperature probe and
keeps the patient adequately volume-filled.
2.3. Peritoneal Cancer Index and completeness of
cytoreduction score
The Peritoneal Cancer Index (PCI) score was used to
describe the extent of peritoneal disease.10 The
completeness of resection was measured prospectively in
all patients using the completeness of cytoreduction (CC)
score. This score, which measures the amount of disease
left behind,11 has been shown in several studies to be the
strongest prognostic indicator in patients with PC under-
going CRS and HIPEC.4,5 Patients with a CC score of 0 and 1
are considered to have achieved optimal cytoreduction
because chemotherapy can penetrate these small nodules.
In patients with a CC score of 2 and 3, surgery does not
provide additional survival benefit when compared to con-
servative management.
Table 2 Patient and operative factors: summary of
operative factors and resections performed.
Variable No. of
patients
Median (range)
PCI 25 12 (1e27)
Operation duration (min) 35 505 (195e960)
Average blood loss (mL) 34 1000 (200e4500)
Hospital stay (d) 35 14 (9e36)
ICU stay (d) 35 1 (0e5)
Time to feeds (d) 35 5 (2e11)
Disease-free interval1 (mo) 35 15.0 (1.7e95.9)
CC score 35 0 (0e3)
Total no. of procedures 35 2 (1e5)
Colectomy 15
Small bowel resection 15
Splenectomy 7
Gastrectomy 1
Total hysterectomy
and bilateral
salpingoopherctomy
(THBSO)
12
Cholecystectomy 5
Bladder resection (wedge) 1
Diaphragmatic peritonectomy 25
CC Z completeness of cytoreduction; ICU Z intensive care
unit; PCI Z Peritoneal Cancer Index.
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Following CRS and HIPEC, four intra-abdominal drains were
left in place, and early postoperative intraperitoneal
chemotherapy (EPIC) was initiated for 5 days. EPIC is used
as the resection site, and stripped peritoneal surfaces are
at high risk for tumor cell implantation in the postoperative
period.10 5-Fluorouracil was the chemotherapy agent used
for EPIC in this group of patients.
The patients were transferred to the surgical intensive
care unit or high dependency unit postoperatively. All
intraoperative and 30-day postoperative complications
were recorded. Morbidity was evaluated using the common
terminology criteria for adverse events version 3.0 of the
National Institute of Health criteria.8
The patients were followed up at the surgical oncology
outpatient unit at the National Cancer Centre Singapore at
approximately 1 week after discharge, and at least every
3e6 months thereafter. At each follow-up visit and when
clinically indicated, CT scans of the thorax, abdomen, and
pelvis were performed, along with tumor markers (as
appropriate). Most of the patients were also followed up
with medical oncologists and received adjuvant systemic
chemotherapy at the discretion of the oncologist. Events of
recurrent disease and their sites were recorded.
2.5. Statistical analysis
The KaplaneMeier method was used to derive the survival
functions forOSandDFS, fromwhichmedianOSandDFSwere
derived. 95% confidence intervals for the medians wereTable 1 Patient and operative factors: patient de-
mographics and primary tumor characteristics.
Variable Frequency
Age (y) 51 (14e71)
Race Chinese 31 (89)
Indian 1 (3)
Others 3 (9)
Sex Female 24 (69)
Male 11 (31)
Histological diagnosis Intestinal 23 (66)
Mucinous 12 (34)
Site of primary tumor Right colon 15 (43)
Left colon 20 (57)
T stage of primary
tumor (n Z 32)
1 1
2 0
3 9
4 22
N stage of primary
tumor (n Z 30)
N0 10
N1 (1e3 LN) 10
N2 (4 or more LN) 10
Grade of primary
tumor (n Z 33)
1 9
2 20
3 4
Disease-free
interval (mo)
15 (1.7e95.9)
Data are presented as n, n (%), or median (range).
LN Z lymph node.calculated using the logelog method. Median follow-up
duration was derived using the reverse KaplaneMeier
method. The effect of individual variables on the occurrence
of postoperative complications was tested with the Man-
neWhitney U test, Pearson c2 test, or Fisher’s exact test,
where appropriate. Logistic regression models were used to
evaluate the effect of multiple variables on the occurrence
of postoperative complications. A two-sided p value of<0.05
was taken as significant. All analyses were performed in
STATA 11.2 (StataCorp LP. http://www.stata.com/).
3. Results
A total of 35 consecutive patients underwent CRS and HIPEC
between January 2001 and December 2012. Preoperative
data are summarized in Table 1. DFI was defined as the time
between primary surgery and recurrence. T and N staging
was based on the American Joint Committee on Cancer
Staging Manual, 7th edition.12
The median PCI was 12, and 33 patients (94%) had a
complete cytoreduction (CC-0). One patient achievedTable 3 Patient and operative factors: high-grade post-
operative complications.
Postoperative complication No. of patients
Respiratory (pleural effusion) 6
Intra-abdominal collection 5
Enterocutaneous fistula 1
Bleeding 2
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Figure 1 KaplaneMeier curves of overall survival (OS).
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Figure 2 KaplaneMeier curves for disease-free survival (DFS).
CRS and HIPEC for colorectal metastases 69optimal cytoreduction with CC-1, and one patient did not
achieve optimal cytoreduction with a CC-3 score. Median
operating time and intraoperative blood loss were 505 mi-
nutes and 1000 mL, respectively. Median intensive care unit
and hospital stays were 1 day and 14 days, respectively. The
procedures and operative factors are summarized in
Table 2.
3.1. Morbidity and mortality
Postoperative complications occurred in 14 patients. For
patients who experienced more than one complication, the
worse grade was used. We observed four low-grade (grades
1 and 2) and 10 high-grade complications (grades 3e5;
Table 3). Pleural effusions and intra-abdominal collections
requiring percutaneous drainage accounted for the major-
ity of the latter. There was one postoperative hemorrhage
necessitating reexploration. There was no 30-day mortality.
On univariate analysis, patients who underwent a
colectomy as part of the CRS and HIPEC were significantly
more likely to experience a postoperative complication. Inaddition, patients who had four or more procedures per-
formed during the CRS and those who received less blood
transfusion were more likely to experience a high-grade
complication. Multivariate analyses were not performed
because of the small number of events.
3.2. OS and DFS
After a median follow-up of 24.7 months (95% CI 0.6e81.8
months), 18 (51.4%) patients recurred and 13 passed away.
Four patients (11.4%) had isolated peritoneal recurrence,
five patients (14.3%) had isolated distant metastasis, and
eight (22.8%) had both peritoneal and distant relapse at
first recurrence. The median time to recurrence for the
patients with isolated peritoneal recurrence, isolated
distant metastases, and both peritoneal and distant relapse
was 10 months, 5 months, and 15 months, respectively. The
median DFS for the 35 patients was 9.4 months (95% CI
5.5e18.7), with 1 year, 3 year, and 5 year DFS at 43.8%,
22.3%, and 22.3%, respectively. The patient’s age at sur-
gery, CC score, and DFI were significant on log-rank test.
70 M.C.C. Teo et al.The N stage showed a trend toward significance, with a
p Z 0.094.
The median OS was calculated to be 27.1 months (95%
CI 15.3e39.1). The 1 year, 3 year, and 5 year OS rates
were 83.7%, 38.2%, and 19.1%, respectively. Factors
influencing OS were age at surgery, N stage, CC score, and
DFI. The KaplaneMeier curves and univariate analysis of
prognostic factors for OS and DFS are depicted in Figs. 1
and 2, and Tables 4 and 5, respectively. Multivariate an-
alyses were not performed owing to the small number of
events.Table 4 Univariate analysis of overall survival (OS).
No. of deaths/no.
of patients
Median OS,
mo (95% CI)
p (l
All patients 14/35 27.1 (15.3e39.1)
Age at peritonectomy
51 y 11/18 17.4 (10.0e36.6)
>51 y 3/17 28.8 (16.2eUD) 0
Histology
Intestinal 8/23 28.8 (14.0eUD)
Mucinous 6/12 27.1 (4.7eUD) 0
T stage
1 0/1 UD (UD)
3 1/9 UD (1.9eUD)
4 11/22 23.2 (14.0e39.1) 0
N stage
0 2/10 36.6 (18.3eUD)
1 2/10 27.1 (17.4eUD)
2 6/10 14.0 (1.9eUD) 0
PCI score
15 5/19 18.3 (10.0eUD)
>15 2/6 UD (1.9eUD) 0
CC score
0 13/33 27.1 (16.2e39.1)
1 1/2 1.9 (UD) <0
No. of procedures
<4 10/28 27.1 (16.2e39.1)
4 4/7 36.6 (1.9eUD) 0
Gastrectomy
No 14/33 23.2 (15.3e39.1)
Yes 0/2 UD (UD) 0
Colectomy
No 6/20 27.1 (14.0eUD)
Yes 8/15 18.3 (4.7e36.6) 0
SB resection
No 10/20 23.2 (10.0e36.6)
Yes 4/15 27.1 (15.3eUD) 0
Splenectomy
No 10/28 23.2 (15.3eUD)
Yes 4/7 27.1 (1.9eUD) 0
Diaphragm
No 1/10 18.3 (18.3eUD)
Yes 13/25 27.1 (14.0e39.1) 0
Disease-free interval
12 mo 8/12 16.2 (1.9e36.6)
>12 mo 6/23 28.8 (18.3eUD) 0
CC Z completeness of cytoreduction; CI Z confidence interval; SB Z4. Discussion
The role of CRS and HIPEC for CPM was established in the
first randomized prospective trial in 2003.2 In the trial, 105
patients with CPM were assigned to either systemic
chemotherapy (5-fluorouracil/lecovorin) with or without
palliative surgery, or CRS and HIPEC with mitomycin C,
followed by systemic chemotherapy. The preliminary re-
sults showed a median survival of 12.6 months and 22.3
months in the standard treatment and CRS and HIPEC arms,
respectively (p Z 0.032), but with a mortality of 8% withog-rank test) Hazard ratio (95% CI) p (Cox model)
1
.038 0.28 (0.08e1.01) 0.033
1
.325 1.73 (0.57e5.23) 0.337
Omitted
1
.676 1.29 (0.16e10.39) 0.805
1
1.67 (0.23e12.19)
.045 5.89 (1.14e30.54) 0.061
1
.470 1.83 (0.35e9.73) 0.496
Model did not converge
.001
1
.986 0.99 (0.31e3.21) 0.986
Model did not converge
.356
1
.342 1.67 (0.58e4.82) 0.344
1
.327 0.56 (0.17e1.81) 0.317
1
.458 1.56 (0.48e5.08) 0.476
1
.492 2.02 (0.26e15.76) 0.458
1
.028 0.32 (0.11e0.93) 0.037
small bowel; UD Z undefined.
Table 5 Univariate analysis of disease-free survival (DFS).
No. of relapses/no.
of patients
Median DFS,
mo (95% CI)
p (log-rank) Hazard ratio (95% CI) p (Cox model)
All patients 18/35 9.4 (5.5e18.7)
Age at peritonectomy
51 y 13/18 7.7 (3.4e12.7) 1
>51 y 5/17 18.7 (5.3eUD) 0.038 0.35 (0.12e0.98) 0.035
Histology
Intestinal 10/23 10.5 (4.8eUD) 1
Mucinous 8/12 9.4 (2.5eUD) 0.325 1.62 (0.62e4.23) 0.333
T stage
1 1/1 UD (UD) 1
3 2/9 UD (1.5eUD) 1.02 (0.09e11.73)
4 13/22 9.4 (7.2e18.7) 0.995 1.08 (0.14e8.45) 0.995
N stage
0 3/10 18.7 (4.7eUD) 1
1 4/10 9.4 (1.9eUD) 2.18 (0.48e9.83)
2 7/10 7.2 (1.5eUD) 0.094 4.14 (1.05e16.42) 0.102
PCI score
15 8/19 9.2 (4.7eUD) 1
>15 3/6 18.7 (1.5eUD) 0.867 1.12 (0.30e4.23) 0.869
CC score
0 17/33 10.5 (7.2e18.7) Model did not converge
1 1/2 1.5 (UD) <0.001
No. of procedures
<4 14/28 9.4 (5.5e18.7) 1
4 4/7 12.7 (1.5eUD) 0.699 0.80 (0.26e2.46) 0.694
Gastrectomy
No 18/33 9.4 (5.5e18.6) Model did not converge
Yes 0/2 UD (UD) 0.191
Colectomy
No 9/20 12.7 (7.2eUD) 1
Yes 9/15 5.3 (2.5e18.6) 0.168 1.90 (0.75e4.83) 0.178
SB resection
No 12/20 9.4 (5.3e18.7) 1
Yes 6/15 18.6 (2.5eUD) 0.364 0.63 (0.24e1.71) 0.358
Splenectomy
No 13/28 9.2 (5.3eUD) 1
Yes 5/7 9.4 (1.5eUD) 0.526 1.40 (0.49e4.01) 0.537
Diaphragm
No 2/10 UD (4.7eUD) 1
Yes 16/25 9.4 (5.3e18.7) 0.398 1.87 (0.43e8.15) 0.368
Disease-free interval
12 mo 9/12 7.2 (1.5e9.4) 1
>12 mo 9/23 18.6 (5.5eUD) 0.008 0.29 (0.11e0.76) 0.014
CC Z completeness of cytoreduction; CI Z confidence interval; SB Z small bowel; UD Z undefined.
CRS and HIPEC for colorectal metastases 71the CRS arm. The study was updated in 2008 and reported
disease-specific survivals of 12.6 months and 22.2 months in
the control and CRS and HIPEC arms,13 respectively. The
trial was criticized for its high mortality rate, and the
chemotherapy regime used in the standard arm is now
outdated. Glehen et al14 conducted the largest study,
involving 506 patients treated at 28 institutions, and re-
ported outcomes of CRS and HIPEC for CPM. Morbidity and
mortality rates of 22.9% and 4%, respectively and OS of 19.2
months were attained.
CRS and HIPEC are gradually becoming accepted as the
standard of treatment for patients with colorectal PC.However, data supporting the use of CRS and HIPEC for
colorectal PC in an Asian population is lacking. In our
cohort, the majority of patients were Chinese, with a
smaller percentage of patients from other communities.
Our Japanese counterparts have reported morbidity and
mortality rates of CRS and HIPEC performed for pseudo-
myxoma peritonei and PC from colorectal and gastric can-
cers15 at 49% and 3.5%, respectively, whereas other
Japanese reports have been on CRS and HIPEC for gastric
cancer, with a reported median OS of 11.5 months, and a 5-
year survival rate of 6.7%.16 To our knowledge, this is the
first study to report on the outcomes for CRS and HIPEC for
72 M.C.C. Teo et al.colorectal PC in Asian patients. Our reported median OS of
27.1 months (95% CI 15.3e39.1) and of 83.7%, 38.2%, and
19.1% at 1 year, 3 years, and 5 years, respectively, is
comparable to that reported in other Western centers.17,18
As with most surgical interventions, the selection of
patients for treatment is crucial for success. The CC score
remains the most important prognostic indication for sur-
vival in patients undergoing CRS and HIPEC.4,19 The PCI
score has also been shown to be a useful prognostic mea-
sure for patients with colorectal or appendiceal PC.7,10 In
our study, the age of the patient, CC score, nodal status,
and the DFI significantly affected OS. The PCI score did not
affect OS, as optimal cytoreduction was achieved in all but
one of our patient. In addition, only 25 of the 35 patients
had records of their PCI score, which may also limit the
analysis of this factor on OS and DFS.
Our younger patients (<52 years) did worse than the
older patients. There are small studies that show that
young colorectal cancer patients have a more aggressive
disease, with poorer survival.20,21 Larger studies depict
young colorectal cancer patients as having later-stage and
higher-grade tumors, but equivalent 5-year cancer-specific
survival compared to older patients.22 However, our study
found that our Asian patients who were aged <51 years at
surgery had a median OS that was 11 months less than that
of older patients (Table 4), but there were fewer patients
(12.5%) with N0 disease in the younger, as compared to the
older group of patients (42%). This may account for the
poorer survival as nodal status affected OS. Patients with
N1 or more fared at least two times worse than patients
with N0 disease (Table 4). We tended to be more aggressive
with younger patients with good ECOG status, willing to
perform CRS and HIPEC even if their DFI was less than 12
months and they had N2 disease. Patients, in whom CC-
0 was not achieved during surgery, also had significantly
inferior OS. The analysis of the CC score was, however,
limited by the small number of patients who had a CC score
of more than 1 (nZ 1). Nevertheless, the CC score remains
an important prognostic indicator and is well established in
the literature.22 Lastly, a DFI of more than 1 year also
provided good OS, as this likely reflected a better tumor
biology and disease profile.
The DFS was similarly affected by age, CC score, and
DFI. Again, our younger patients tended to recur earlier.
Patients in whom CC-0 was not achieved also had signifi-
cantly inferior DFS, as did patients with DFI of less than 1
year (Table 5). As shown in the KaplaneMeier curve (Fig. 1),
the majority of patients who were disease-free after 2
years, remained disease-free, whereas patients who had
recurrence of disease tended to recur early, i.e., within the
first 2 years. This can be explained by the fact that PC
behaves like a locoregional disease, and when recurrences
occur, they tend to recur early. The absence of disease at 2
years after CRS portends good survival results. Conse-
quently, it is vital to select patients with a low risk of sys-
temic metastases that can be predicted by nodal status and
DFI. This is further supported by the analysis showing that
nodal status significantly affected OS in our patients. In this
group of patients with “high-risk” features, we propose a
plan of watchful waiting with or without systemic chemo-
therapy, and repeat imaging in 3 months. In the event that
they remain systemically free of metastases, CRS and HIPECcan then be planned. This facilitates better selection of
patients, allowing us to perform CRS and HIPEC for patients
who will derive the greatest benefits.
In our study, among the 34 patients who underwent CRS
and HIPEC, 10 patients (28%) suffered major complica-
tions, the majority of which were pleural and intra-
abdominal collections requiring percutaneous drainage.
Since 2010, have we placed pleural and subdiaphragmatic
drainage catheters intraoperatively, if the diaphragmatic
peritoneum is stripped, to reduce intra-abdominal collec-
tions.23 This is likely to improve our morbidity rates with
the next analysis. Patients who underwent a colectomy as
part of the CRS or had more than four procedures per-
formed, were more likely to experience a postoperative
complication.
Patients undergoing CRS and HIPEC experience signifi-
cant pathophysiological alterations during surgery, i.e.,
massive blood loss and raised intra-abdominal pressure.24
Perioperative anesthetic care is critical in the CRS and
HIPEC. Postoperative complications are reduced when pa-
tients are kept well resuscitated intraoperatively. This is
also suggested by our analysis showing that patients with
fewer intraoperative blood transfusions were more prone to
major complications, indicating that patients who were
under-resuscitated during the surgery suffered from higher
grade complications, whereas those who received adequate
blood products had fewer high-grade complications.
5. Conclusion
Our data show that CRS and HIPEC can provide survival
benefits, with reasonable morbidly and mortality for Asian
patients with PC from colorectal cancer. The key to the
success of the procedure lies in patient selection and
perioperative management of the patients.
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